Handelsavisen
prelaunch
Companies Energy FREG.DE
FR
FREG.DE XETRA Oil & Gas Exploration & Production

Fresenius SE & Co KGaA

€38,80
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
2,43 %
Op margin
9,7 %
ROE
7,7 %
Net margin
6,4 %
Debt / equity
0,62
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Fresenius SE & Co KGaA operates as a global healthcare group providing hospital services, medical products, and dialysis care, generating revenue through service fees and product sales.

Business. Fresenius SE & Co KGaA (FREG.DE) is a company engaged in the exploration and production of oil and gas. The firm operates within the Oil & Gas industry, generating revenue through product sales. It is primarily listed on the Xetra exchange. Specific details regarding operating segments and geographic distribution are not available.

Classification62 %
SectorEnergy
Business sectorOil & Gas
IndustryOil & Gas Exploration & Production
ActivityExploration & Production
Generated · model-assisted
Sell-side consensus
BUY18 analysts
17 buy1 hold0 sell
Avg 12m price target53,42

Analyst recommendations

18 analysts · consensus Buy
Buy17
Hold1
Sell0
12-month price target
53,42
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
18 analysts · indicative
Ownership
not yet wired
Profitability
7,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning FREG.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy · THIS SECTOR+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to FREG.DE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Fresenius SE & Co KGaA (FREG.DE) is a company engaged in the exploration and production of oil and gas. The firm operates within the Oil & Gas industry, generating revenue through product sales. It is primarily listed on the Xetra exchange. Specific details regarding operating segments and geographic distribution are not available.

    Classification62 %
    SectorEnergy
    Business sectorOil & Gas
    IndustryOil & Gas Exploration & Production
    ActivityExploration & Production
    AI synthesis
    GENERATED

    Fresenius maintains a leveraged capital structure with total liabilities of €22.3 billion against total equity of €19.1 billion, resulting in a debt-to-equity ratio of 0.62. The company holds €111 million in cash and equivalents, which is insufficient to cover its €11.8 billion in long-term debt, creating a net cash deficit. Liquidity is supported by a current ratio of 1.32, indicating adequate short-term asset coverage for current liabilities. Operating cash flow stands at €2.57 billion, while free cash flow is €545 million after capital expenditures of €1.49 billion.

    Profitability metrics show a return on equity of 7.69% and a return on assets of 3.55%. The company generated €22.87 billion in revenue, with a gross profit of €5.69 billion and operating income of €2.31 billion. Net income reached €1.26 billion. Without cohort median data provided in the input, these returns are assessed in isolation, showing modest leverage-adjusted profitability.

    Key takeaways
    • Fresenius generates €22.87 billion in revenue with €1.26 billion in net income, yielding a 7.69% ROE.
    • The company carries €11.8 billion in long-term debt against €111 million in cash, resulting in a negative net cash position.
    • Liquidity is moderate with a current ratio of 1.32 and operating cash flow of €2.57 billion.
    • Analyst sentiment is positive with a mean recommendation of 1.61 and a median price target of €54.00.
    • Dilution risk is low with no difference between basic and diluted share counts.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Analysts project 37.7% upside to a mean price target of EUR 53.42, reflecting strong buy consensus among 18 analysts.

    Net income surged 168.4% year-over-year to EUR 1.26 billion in FY2026, demonstrating significant profitability recovery.

    Long-term debt decreased substantially to EUR 11.83 billion in FY2026, improving the balance sheet from EUR 27.16 billion in FY2022.

    Cash conversion ratio of 1.75 exceeds the cohort median of 1.22, indicating superior efficiency in generating cash from earnings.

    Operating income grew 11.4% year-over-year to EUR 2.31 billion in FY2026, signaling expanding operational profitability.

    BEAR CASE · 1

    The company faces high credit risk, posing a significant threat to financial stability and potential borrowing costs.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-06
    Q1 2026 · Quarter highlights

    Revenue €5.82B, +2,0% YoY; Operating income −12,6% YoY.

    Revenue€5.82B+2,0 % YoY
    Operating income€602.0M−12,6 % YoY
    Net income€435.0M+90,0 % YoY
    Free cash flow€472.0M+7,3 % YoY
    EPS
    Operating cash flow€389.0M+1 241,4 % YoY
    Financials
    Income statement
    Revenue€5.82B
    Gross profit€1.53B
    Operating income€602.0M
    Net income€435.0M
    Margins
    Gross margin26.4%
    Operating margin10.3%
    Net margin7.5%
    FCF margin8.1%
    Balance sheet
    Total assets€42.37B
    Total liabilities€22.59B
    Total equity€19.78B
    Cash & equivalents€2.06B
    Long-term debt€11.82B
    Cash flow
    Operating cash flow€389.0M
    CapEx-€246.0M
    Free cash flow€472.0M
    SBC
    P&L flow · revenue → net income
    Revenue €5.82BOperating costs €5.22BTax €167.0MNet income €435.0M
    Highlights
    • Revenue €5.82B, +2,0% YoY
    • Operating income −12,6% YoY
    • Net income +90,0% YoY
    • Free cash flow +7,3% YoY
    • Net margin 7.5%

    Valuation TTM

    Market price
    €38,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €19.10B
    Net cash
    -€11.72B
    Current ratio
    1.3
    Debt / equity
    0.6
    ROA
    3.5%
    ROE
    7.7%
    Cash conversion
    175.0%
    CapEx / revenue
    -6.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Active Pharmaceutical Ingredients (API)
    low · llm_fanout_v2
    Bulk Pharmaceutical Enzymes
    low · llm_fanout_v2
    Over-the-Counter (OTC) Healthcare
    low · llm_fanout_v2
    Pharmaceutical Distribution
    low · llm_fanout_v2

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 44 %
    EPS
    Consensus EPS
    3,55
    Predicted surprise
    -0,01
    Beat probability
    44 %
    Analysts
    18
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio -0,03 · as of 2026-07-07 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate3,55
    Revenueno estimateno estimate23,6B EUR
    Operating incomeno estimateno estimate2,7B EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution18 analysts
    Strong buy8
    Buy9
    Hold1
    Sell0
    Strong sell0
    12-month price target€53,42 · Median €54,00
    Low €48,00High €58,00
    Operating income · consensus2,7B EUR
    EPS surprise
    −0,2 %
    reported vs consensus · miss
    Revenue surprise
    −3,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€48,00
    Mean€53,42
    Median€54,00
    High€58,00
    Spot€38,80
    +37.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin9,7 %Below median
    Net Margin6,4 %Below median
    ROE7,7 %Below median
    Capex / Rev-6,5 %Below median
    D/E0,62Below median
    Cash Conv1,75Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Physical assets

    2 tracked
    AssetTypeCommodityCountryRole
    St. Wendel power stationPowerPowerGermanyParent
    St. Wendel power stationPowerOil & GasGermanyParent
    Tracked physical assets associated with this issuer (operated, managed, or owned).

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Return On Assets
      net_income / total_assets
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Fresenius SE & Co KGaA Market data — financials · 2026-07-07
    • Fresenius SE & Co KGaA Market data — analyst estimates · 2026-07-07
    • Fresenius SE & Co KGaA Market data — ESG · 2026-07-07
    • Fresenius SE & Co KGaA — company reference export (2026-07-05) · 2026-07-07

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data
    Index membership
    DAX

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    FREG.DECanonical
    XETRA · EUR

    Intel & risk

    PredictorBeat prob44 %Surprise-0,01Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-05-06 05:48 UTCEARNINGSQuarterly results — Q1 2026 Revenue EUR 5.82B · Net EUR 435.0M
    2026-02-25 08:54 UTCEARNINGSQuarterly results — Q4 2025 Revenue EUR 6.16B · Net EUR 361.0M
    2026-02-25 08:54 UTCEARNINGSAnnual results — FY 2026 Revenue EUR 22.87B · Net EUR 1.26B
    2025-11-05 08:04 UTCEARNINGSQuarterly results — Q3 2025 Revenue EUR 5.49B · Net EUR 344.0M
    2025-08-06 06:22 UTCEARNINGSQuarterly results — Q2 2025 Revenue EUR 5.58B · Net EUR 330.0M
    2025-05-07 06:23 UTCEARNINGSQuarterly results — Q1 2025 Revenue EUR 5.71B · Net EUR 229.0M
    2025-02-26 06:20 UTCEARNINGSQuarterly results — Q4 2024 Revenue EUR 5.85B · Net EUR 240.0M
    2025-02-26 06:20 UTCEARNINGSAnnual results — FY 2025 Revenue EUR 21.95B · Net EUR 471.0M
    2024-11-06 16:18 UTCEARNINGSQuarterly results — Q3 2024 Revenue EUR 5.32B · Net EUR 326.0M
    2024-07-31 16:11 UTCEARNINGSQuarterly results — Q2 2024 Revenue EUR 5.44B · Net EUR -373.0M
    2024-02-21 11:42 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 21.07B · Net EUR -594.0M
    2023-02-21 00:00 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 21.53B · Net EUR 1.37B
    2022-02-22 08:30 UTCEARNINGSAnnual results — FY 2022 Revenue EUR 37.52B · Net EUR 1.82B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage